ATAP peptides, nucleic acids encoding the same and associated methods of use

Patent metadata

Field	Value
Publication number	US-9505821-B2
Application number	US-44428807-A
Country	US
Kind code	B2
Filing date	Oct 3, 2007
Priority date	Oct 3, 2006
Publication date	Nov 29, 2016
Grant date	Nov 29, 2016

Abstract

Disclosed herein are nucleic acid sequences that encode pro-apoptotic polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of proliferative disorders and bacterial infections using the nucleic acids and proteins of the invention.

First claim

The invention claimed is:

1. An isolated polypeptide comprising SEQ ID NO:36, an analog or derivative thereof, wherein the polypeptide, analog, or derivative thereof forms pores in the mitochondrial outer membrane, wherein the polypeptide, analog, or derivative thereof is 29 to 60 amino acids long.

2. An isolated polypeptide, wherein the polypeptide is a member selected from the group consisting of SEQ ID NO. 36, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, and 51.

3. A fusion protein comprising:
a first polypeptide including the amino acid sequence of general formula (I):
bXaXbuunnunnanXGbnXannXnn(X) 0-2 bXYC  (I)

wherein,
n=a nonpolar (hydrophobic) amino acid;
X=any amino acid;
u=a polar, uncharged amino acid;
b=a basic amino acid;
a=an acidic amino acid; and wherein the first polypeptide forms pores in the mitochondrial outer membrane; and

at least one additional heterologous peptide disposed at any one of the amino terminus, the carboxy terminus, or both, and wherein the first polypeptide and the additional heterologous peptide are disposed in a single, contiguous polypeptide chain of 31 to 60 amino acids long.

4. The fusion protein of claim 3 , wherein the at least one additional polypeptide comprises a TAT polypeptide or portion thereof.

5. The fusion protein of claim 4 , wherein the fusion protein further comprises a HIS tag.

6. A therapeutic composition comprising a pharmaceutically acceptable excipient or carrier, and an effective amount of a polypeptide comprising the amino acid sequence of general formula (I):
bXaXbuunnunnanXGbnXannXnn(X) 0-2 bXYC  (I)

wherein,
n=a nonpolar (hydrophobic) amino acid;
X=any amino acid;
u=a polar, uncharged amino acid;
b=a basic amino acid;
a=an acidic amino acid; and
the polypeptide forms pores in the mitochondrial outer membrane and 29 to 60 amino acids long.

7. The therapeutic composition of claim 6 , wherein the polypeptide is at least one member selected from the group consisting of SEQ ID NO. 36, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, and 50.

8. An isolated polypeptide comprising the general formula (II):
(K/R)n(E/D)(P)(K/R)(S/T)GW(M/L)(S/T)FL(E/D)nTG(K/R)(I/V/L)(X)(E/D)ML(X) 1-6 LL(X) 0-2 (K/R)XYC  (II)

wherein,
n=a nonpolar (hydrophobic) amino acid; and
X=any amino acid, wherein the polypeptide forms pores in the mitochondrial outer membrane and is 29 to 60 amino acids long.

9. A method of treating a bacterial infection comprising administering to a subject an effective amount of composition comprising the composition of claim 6 , together with a pharmaceutically acceptable carrier.

10. A composition comprising a pharmaceutically acceptable carrier and an effective amount of a peptide with the sequence as set forth in SEQ ID NO.: 36 and is 29 to 60 amino acids long.

11. An isolated polypeptide comprising the amino acid sequence of general formula:
(K/R)X(E/D)X(K/R)uunnunn(E/D)nXG(K/R)nX(E/D)nnXnn(K/R) 1-2 (X) 1-4 C
wherein,
n=a nonpolar (hydrophobic) amino acid;
X=any amino acid,
u=a polar, uncharged amino acid; and
the polypeptide forms pores in the mitochondrial outer membrane and is 29 to 60 amino acids long.

12. A composition comprising a pharmaceutically acceptable carrier and an effective amount of the polypeptide of claim 11 .

Assignees

• Ma Jianjie
• Ko Jae-Kyun
• Kim Chul-Woo
• Weisleder Noah
• Univ Rutgers

Inventors

• Ma Jianjie
• Ko Jae-Kyun
• Kim Chul-Woo
• Weisleder Noah

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• C07K14/4747 Primary

  Apoptosis related proteins · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• C07K2319/10

  containing a tag for extracellular membrane crossing, e.g. TAT or VP22 · CPC title